Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists

Bioorg Med Chem. 2013 Oct 1;21(19):5983-94. doi: 10.1016/j.bmc.2013.07.043. Epub 2013 Jul 31.

Abstract

Dihydrofuran-2-one and dihydropyrrol-2-one derivatives were identified as novel, potent and selective mineralocorticoid receptor (MR) antagonists by the structure-based drug design approach utilizing the crystal structure of MR/compound complex. Introduction of lipophilic substituents directed toward the unfilled spaces of the MR and identification of a new scaffold, dihydropyrrol-2-one ring, led to potent in vitro activity. Among the synthesized compounds, dihydropyrrol-2-one 11i showed an excellent in vitro activity (MR binding IC50=43nM) and high selectivity over closely related steroid receptors such as the androgen receptor (AR), progesterone receptor (PR) and glucocorticoid receptor (GR) (>200-fold for AR and PR, 100-fold for GR).

Keywords: Aldosterone; MR; Mineralocorticoid receptor; Nonsteroidal.

MeSH terms

  • Animals
  • Benzofurans / chemistry*
  • Benzoxazines / chemistry*
  • COS Cells
  • Chlorocebus aethiops
  • Crystallography, X-Ray
  • Drug Design*
  • Inhibitory Concentration 50
  • Mineralocorticoid Receptor Antagonists / chemical synthesis*
  • Mineralocorticoid Receptor Antagonists / chemistry
  • Mineralocorticoid Receptor Antagonists / pharmacology
  • Protein Binding / drug effects
  • Pyrroles / chemistry*
  • Structure-Activity Relationship

Substances

  • Benzofurans
  • Benzoxazines
  • Mineralocorticoid Receptor Antagonists
  • Pyrroles
  • benzo(b)-2,3-dihydrofuran-2-one
  • pyrroline